EUCTR2014-002267-15-DKActive, not recruitingPhase 1
Treatment of hypoglycemia with glucagon among patients with type 1 diabetes mellitus - GluST1
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Hvidovre Hospital
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •-Males and females aged 18-65 years
- •-Diagnosed with type 1 diabetes > 3 years
- •-HbA1c < 58 mmol/mol
- •-No appearance of autonome neuropathy
- •-Body mass index (BMI) between 20-25 kg/m2
- •-Remained hypoglycæmic awareness
- •-Insulin pump treatment > 1 year
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Allergic to glucagon or lactose
- •Pregnancy, breast-feeding, intention of becoming pregnant, or not using adequate contraception
- •Any disease or condition which would interfere with the subject's safety
- •Use of a medication that significantly impacts glucose metabolism
Investigators
Similar Trials
Unknown
Phase 4
Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 DiabetesDiabetes Mellitus, Type 1NCT02232971Hvidovre University Hospital8
Completed
Not Applicable
Effective treatment of hypoglycaemia in children with type 1 diabetes: A randomised controlled clinical trialHypoglycaemiaMetabolic and Endocrine - DiabetesACTRN12609000129280Esko Wiltshire160
Completed
Not Applicable
Mini-Dose Glucagon to Treat Fasting-induced Hypoglycemia During RamadanFasting HypoglycemiaDiabetes Mellitus, Type 1NCT03970772Qassim University20
Withdrawn
Phase 2
Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 DiabetesType 1 DiabetesNCT01828125Institut de Recherches Cliniques de Montreal
Completed
Not Applicable
The effectiveness of oral hypoglycemic agents in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. -Multiple comparison, Dapagliflozin, Pioglitazone vs Glimepirideonalcoholic fatty liver disease patients with type 2 diabetesJPRN-UMIN000021291Kawasaki Medical SchoolKawasaki Medical School Devision of Diabetes, Endocrinology and Metabolism90